ETF日报：近期创新药对外授权交易频现突破，预计仍有优质国产品种具备出海潜力，可关注创新药ETF国泰

Market Overview - A-shares experienced a strong rebound today, with the Shanghai Composite Index rising by 0.48% to 3683.46 points, marking a new high since December 2021 [1] - The Shenzhen Component increased by 1.76%, the ChiNext Index by 3.62%, and the STAR Market Index by 1.49% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 2.15 trillion yuan, an increase of 269.4 billion yuan compared to the previous trading day [1] - Technology-related sectors led the gains, particularly in communications, artificial intelligence, and innovative pharmaceuticals, while dividend sectors like coal, finance, oil, and transportation lagged [1] Economic and Policy Insights - The market is currently focused on tariff disruptions and the pace of interest rate cuts in the U.S. [1] - The Trump administration's recent decision to extend tariffs on certain goods by 90 days aligns with market expectations, but concerns remain regarding "secondary tariffs" on Indian products due to energy purchases from Russia [2][1] - Analysts suggest that the secondary tariffs may be a strategic move to pressure China regarding the Russia-Ukraine conflict [2] Inflation and Interest Rate Outlook - Despite concerns that tariffs could lead to long-term inflationary pressures, actual inflation growth is not meeting expectations [3] - Predictions indicate that the year-end CPI may reach 3.2%, with a gradual peak expected [3] - The recent U.S. CPI data falling below expectations has created conditions for potential interest rate cuts in September [2] Sector Performance - The communication ETF (515880) saw a daily increase of 6.45%, driven by significant gains in optical module stocks, which constitute over 40% of the ETF's index [3] - The entrepreneurial AI ETF (159388) rose by 5.50%, benefiting from explosive growth in AI computing demand and product technology iterations [3] - The innovative pharmaceutical sector rebounded strongly, with the innovative drug ETF (517110) increasing by 4.05% [7] Innovative Pharmaceuticals - The innovative drug sector showed a mixed performance in the first half of the year, with leading companies achieving high growth while some faced short-term pressures [9] - The sector's growth is driven by product volume increases, business development (BD) overseas, and favorable procurement policies [9] - The Chinese innovative drug BD transaction volume reached 26.3 billion USD in the first half of 2025, accounting for 33% of the global market, up from 17% in 2021 [9] AI and Technology Developments - Huawei introduced a new technology, UCM, aimed at transforming the AI inference industry by efficiently managing large amounts of memory data [5] - The domestic AI application landscape is expected to follow the capital expenditure model of overseas giants like Meta and Microsoft, focusing on infrastructure investments [6] - Investors are encouraged to consider opportunities in communication ETFs and entrepreneurial AI ETFs to capitalize on the upward trend in the AI supply chain [6]